SCHEDULE: Goldman Sachs Files Schedule 13G for Amicus Therapeutics
Schedule 13G Filing
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G regarding their beneficial ownership of Amicus Therapeutics, Inc. common stock.
Summary
- This filing is an amendment to a Schedule 13G, indicating a change in the reporting status of beneficial ownership for Amicus Therapeutics, Inc. common stock.
- The reporting persons are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.
- The filing states that as of June 30, 2026, both reporting entities hold 0.00 shares of Amicus Therapeutics, Inc. common stock, representing 0.0% of the class.
- This indicates that Goldman Sachs no longer holds a reportable beneficial ownership stake in Amicus Therapeutics, Inc. as of the filing date.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, with no new financial or strategic information impacting the company's valuation.
Negatives
- Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report holding 0.00 shares of Amicus Therapeutics, Inc. common stock, indicating no beneficial ownership.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Amicus Therapeutics, Inc. It pertains solely to the reporting of beneficial ownership by Goldman Sachs entities.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant shareholders. The absence of any reported beneficial ownership by Goldman Sachs entities suggests a divestment or a change in their investment strategy concerning Amicus Therapeutics, Inc., which is common in the dynamic biotechnology sector.
Stakeholder Impact
- Shareholders may note the change in reporting status for Goldman Sachs entities, which could be interpreted in various ways regarding institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 07/16/2025 | Superseded Power of Attorney date for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| 07/02/2026 | Effective date for Power of Attorney for Goldman Sachs & Co. LLC. |
| 07/08/2026 | Effective date for Power of Attorney for The Goldman Sachs Group, Inc. |
| 06/30/2026 | Date of event requiring filing of this statement. |
| 07/17/2026 | Date of filing for the amended Schedule 13G. |
| 07/02/2027 | Expiration date for Power of Attorney for Goldman Sachs & Co. LLC. |
| 07/08/2027 | Expiration date for Power of Attorney for The Goldman Sachs Group, Inc. |
Keywords
Schedule 13G, Beneficial Ownership, Amicus Therapeutics, Goldman Sachs, Amendment, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.